Multiple Myeloma Research Foundation (MMRF) Announces Janssen Research & Development, LLC Joins Innovative Pre-competitive

  Multiple Myeloma Research Foundation (MMRF) Announces Janssen Research &
  Development, LLC Joins Innovative Pre-competitive Consortium to Advance
  Personalized Medicine Approaches for Multiple Myeloma

        Unique Collaboration Supports Landmark Multiple Myeloma Study

Business Wire

NORWALK, Conn. -- June 20, 2013

The Multiple Myeloma Research Foundation (MMRF) today announced that Janssen
Research & Development, LLC (Janssen R&D) has joined the MMRF pre-competitive
consortium (PCC) to discover and accelerate new approaches to treating
multiple myeloma through the organization’s Personalized Medicine Initiative

The cornerstone of the PMI is the landmark MMRF CoMMpass℠ Study (Relating
Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic
Profile) which is collecting cutting-edge, comprehensive clinical information
and molecular profiles of 1,000 newly diagnosed patients over a minimum of
five years. Data collected from CoMMpass will provide researchers with
insights needed to more completely characterize the genetic subtypes of
multiple myeloma based on responsiveness to specific treatment regimens,
ultimately enabling individualized treatment approaches for multiple myeloma.

The study, which opened to enrollment in July 2011, has more than 50 active
sites that have screened more than 300 patients to date. Later this year,
CoMMpass study data will be made available to academic and industry
researchers worldwide via a publicly shared data system to enable open access
analysis, and worldwide collaboration to stimulate hypothesis generation.

Members of the PCC provide scientific and financial support for the PMI. This
innovative, collaborative and diverse partnership structure provides
researchers access to the findings from CoMMpass, to accelerate drug discovery
and development in multiple myeloma and potentially other cancers sharing the
same targets.

“Our partnership with the oncology industry’s leaders will help to drive
scientific and clinical innovation through new models of collaboration,”
stated Walter M. Capone, Chief Operating Officer of the MMRF. “We are deeply
gratified to have Janssen R&D join this breakthrough initiative, and sincerely
appreciate all the members of the PCC for their vision, commitment, and
support of our mission to accelerate the translation of research findings into
therapeutic advancements for patients.”

About Multiple Myeloma

Multiple myeloma is an incurable blood cancer. The five-year relative survival
rate for multiple myeloma is approximately 41 percent, one of the lowest of
all cancers. In 2013, more than 22,000 adults in the United States will be
diagnosed with multiple myeloma and nearly 11,000 people are predicted to die
from the disease.

About the Multiple Myeloma Research Foundation (MMRF)

The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a
501(c)(3) non-profit organization by twin sisters Karen Andrews and Kathy
Giusti, soon after Kathy's diagnosis with multiple myeloma. The mission of the
MMRF is to relentlessly pursue innovative means that accelerate the
development of next-generation multiple myeloma treatments to extend the lives
of patients and lead to a cure. As the world's number-one private funder of
multiple myeloma research, the MMRF has raised over $225 million since its
inception and directs 90% of total budget to research and related programming.
As a result, the MMRF has been awarded Charity Navigator’s coveted four-star
rating for ten consecutive years, the highest designation for outstanding
fiscal responsibility and exceptional efficiency. For more information about
the MMRF, please visit


Anne Quinn Young, MPH
Press spacebar to pause and continue. Press esc to stop.